Mixed results from phase 2 CALLIPER trial of novel dual-action compound
Selective DHODH inhibitor designed as a better-tolerated alternative to teriflunomide
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement